Breaking News Instant updates and real-time market news.

POL

PolyOne

$15.10 /

+0.49 (+3.35%)

15:19
03/23/20
03/23
15:19
03/23/20
15:19

PolyOne upgraded to Buy from Hold at Stifel

Stifel upgraded PolyOne to Buy from Hold.

POL PolyOne
$15.10 /

+0.49 (+3.35%)

03/23/20 Wells Fargo
PolyOne price target lowered to $23 from $42 at Wells Fargo
01/14/20 Wells Fargo
PolyOne upgraded to Overweight from Equal Weight at Wells Fargo
10/15/19 Wells Fargo
PolyOne initiated with a Market Perform at Wells Fargo
10/15/19 Wells Fargo
PolyOne initiated with a Market Perform at Wells Fargo

TODAY'S FREE FLY STORIES

Conference/Events
General Mills management to meet with Piper Sandler » 04:55
03/31/20
03/31
04:55
03/31/20
04:55
GIS

General Mills

$54.11 /

+2.32 (+4.48%)

Meetings to be held in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

General news
4-Week Bill Announcement to be released at 11:00  04:55
03/31/20
03/31
04:55
03/31/20
04:55
 
Conference/Events
Marinus Pharmaceuticals to host a virtual special shareholder meeting » 04:55
03/31/20
03/31
04:55
03/31/20
04:55
MRNS

Marinus Pharmaceuticals

$1.83 /

+ (+0.00%)

Virtual Special…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Cavco Industries management to meet with Craig Hallum » 04:55
03/31/20
03/31
04:55
03/31/20
04:55
CVCO

Cavco Industries

$148.20 /

-7.835 (-5.02%)

Meetings to be held in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
EnerSys management to meet with Oppenheimer » 04:55
03/31/20
03/31
04:55
03/31/20
04:55
ENS

EnerSys

$48.95 /

+1.64 (+3.47%)

Meetings to be held in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Everi Holdings management to meet with SunTrust » 04:55
03/31/20
03/31
04:55
03/31/20
04:55
EVRI

Everi Holdings

$3.37 /

+0.035 (+1.05%)

Meetings to be held in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

General news
Week of 3/28 Redbook to be released at 08:55  04:55
03/31/20
03/31
04:55
03/31/20
04:55
 
General news
8-Week Bill Announcement to be released at 11:00  04:55
03/31/20
03/31
04:55
03/31/20
04:55
 
Upgrade
Sirius XM upgraded to Buy from Neutral at Citi » 04:54
03/31/20
03/31
04:54
03/31/20
04:54
SIRI

Sirius XM

$4.79 /

-0.15 (-3.04%)

Citi analyst Jason…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Sanderson Farms upgraded to Overweight from Equal Weight at Barclays » 04:53
03/31/20
03/31
04:53
03/31/20
04:53
SAFM

Sanderson Farms

$122.16 /

+2.98 (+2.50%)

Barclays analyst Benjamin…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Illinois Tool Works downgraded to Hold from Buy at Jefferies » 04:52
03/31/20
03/31
04:52
03/31/20
04:52
ITW

Illinois Tool Works

$142.16 /

+1.5 (+1.07%)

Jefferies analyst Stephen…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Swiss Re upgraded to Buy from Sell at UBS » 04:48
03/31/20
03/31
04:48
03/31/20
04:48
SSREY

Swiss Re

$0.00 /

+ (+0.00%)

UBS double upgraded Swiss…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Amarin downgraded to Hold from Buy at Jefferies » 04:47
03/31/20
03/31
04:47
03/31/20
04:47
AMRN

Amarin

$13.59 /

+0.34 (+2.57%)

Jefferies analyst Michael…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

General news
FX Action: USD-CAD reached a six-day high » 04:15
03/31/20
03/31
04:15
03/31/20
04:15

FX Action: USD-CAD…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

General news
FX Update: The dollar has traded firmer for a second day » 03:45
03/31/20
03/31
03:45
03/31/20
03:45

FX Update: The dollar has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

General news
China's official March manufacturing and services indexes bounced » 22:20
03/30/20
03/30
22:20
03/30/20
22:20

China's official…

China's official March manufacturing and services indexes bounced from record lows in February, with the composite index improving too. The CFLP manufacturing index rebounded 16.3 points to 52.0 after, more than recouping the 14.3 point drop to 35.7 in February. This is now the highest print since September 2017. The services index rose 22.7 points to 52.3 after plummeting 24.5 points to 29.6 in February. The composite index rose to 53.0 after falling 24.1 points in February to 28.9. Analysts expected a modest rebound in producer sentiment as China partially reopened, but the big jumps will be taken with a grain of salt. The fact that China is rethinking some of its policies on worries of a second wave of the virus, and given the shuttering of much of the world (China's markets), analysts suspect outlooks might be dampened again in April. Nevertheless, the data are likely to provide some impetus for a rally in Asian share markets, especially with the momentum from the 3% gains on Wall Street.

Recommendations
Motus GI Holdings price target lowered to $3 from $4 at Piper Sandler » 20:43
03/30/20
03/30
20:43
03/30/20
20:43
MOTS

Motus GI Holdings

$0.67 /

-0.03 (-4.29%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien lowered the firm's price target on Motus GI Holdings to $3 from $4 and keeps an Overweight rating on the shares. The analyst notes that the company continues to see significant interest in Pure-Vu as it continues to pursue a "focused key account strategy", but because of COVID-19, he sees some elongation in its sales cycle. Accordingly, O'Brien notes that Motus is taking cost containment steps to reduce its cash burn, though he sees the company on solid footing financially.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
CytomX Therapeutics payment for CX-2029 notable milestone, says Piper Sandler » 20:39
03/30/20
03/30
20:39
03/30/20
20:39
CTMX

CytomX Therapeutics

$6.72 /

+0.36 (+5.66%)

, ABBV

AbbVie

$75.32 /

+2.76 (+3.80%)

Piper Sandler analyst…

Piper Sandler analyst Joseph Catanzaro keeps his Overweight rating and $18 price target on CytomX Therapeutics (CTMX), saying the $40M milestone payment from its partner Abbvie (ABBV) related to its achievement of Phase I dose-escalation criteria for CX-2029 is notable. The analyst adds that the announcement implies that a "move-forward" dose has been identified, and the two partners are now finalizing plans for Phase II expansion cohorts in select tumor types.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Notable companies reporting before tomorrow's open » 20:25
03/30/20
03/30
20:25
03/30/20
20:25
MKC

McCormick

$143.00 /

+10.75 (+8.13%)

, CAG

Conagra Brands

$28.35 /

+0.47 (+1.69%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include McCormick (MKC), consensus $1.03... Conagra Brands (CAG), consensus 49c.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Goldman Sachs semiconductors analyst to hold an analyst/industry conference call » 20:25
03/30/20
03/30
20:25
03/30/20
20:25

Semiconductors &…

Semiconductors & Semiconductors Capital Equipment Analyst Hari discuss recalibrating the COVID-19 impact the industry on an Analyst/Industry conference call to be held on March 30 at 8:30 pm. Webcast Link

Upgrade
Vale upgraded to Buy from Neutral at Goldman Sachs » 20:13
03/30/20
03/30
20:13
03/30/20
20:13
VALE

Vale

$8.04 /

+0.205 (+2.62%)

Goldman Sachs analyst…

Goldman Sachs analyst Thiago Ojea upgraded Vale to Buy from Neutral. The analyst is citing improvement in China steel demand, noting 2% annualized growth and inventory reduction of about 5% over the past week. Ojea adds that Vale shares are down about 23% - a larger decline than that of its peers' 10%. The analyst further anticipates additional Chinese infrastructure-based stimulus, which should continue to support steel demand.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
PG&E resolves $4M Butte County fine issue » 20:08
03/30/20
03/30
20:08
03/30/20
20:08
PCG

PG&E

$9.64 /

+ (+0.00%)

PG&E announced that…

PG&E announced that the satisfaction of the $4 million in fines and expenses associated with the plea agreement with the Butte County District Attorney will not reduce the amount of funds available to satisfy wildfire victim claims under PG&E's Plan of Reorganization. The $4 million amount will be funded to the Fire Victim Trust from income earned on the distribution to be made to the subrogation claimants under the Plan. As a result, there will be no reduction in the amount available for wildfire victims. This resolution ensures that PG&E will remain in full compliance with the funding commitments it has obtained that are critical to its timely and successful emergence from Chapter 11, and, most importantly, to expedite the fair and timely payments to victims.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Superior Energy discloses NYSE continued listing notice » 20:00
03/30/20
03/30
20:00
03/30/20
20:00
SPN

Superior Energy

$1.53 /

+0.155 (+11.31%)

Superior Energy announced…

Superior Energy announced it has received written notice from the NYSE that the company is not in compliance with the NYSE continued listing standard set forth in Rule 802.01B of the NYSE Listed Company Manual, which requires the average global market capitalization over a consecutive 30 trading-day period to be greater than or equal to $50,000,000, unless at the same time the stockholders' equity is equal to or greater than $50,000,000. The company will submit the plan to the NYSE within 45 days of its receipt of the notice.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Escalade names Scott Sincerbeaux as CEO » 19:57
03/30/20
03/30
19:57
03/30/20
19:57
WWW

Wolverine World Wide

$15.86 /

+0.53 (+3.46%)

, ESCA

Escalade

$5.75 /

+0.04 (+0.70%)

Escalade (ESCA) is…

Escalade (ESCA) is pleased to announce the appointment of Scott Sincerbeaux as CEO. He will join Escalade on April 27, 2020. Sincerbeaux joins Escalade from Wolverine World Wide (WWW) where he held several positions including President of The Stride Rite Children's Group, President of Direct to Consumer, and President of Global Retail.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Amarin shares plummet 67% after Vascepa patents ruled invalid » 19:48
03/30/20
03/30
19:48
03/30/20
19:48
HKMPF

Hikma Pharmaceuticals

$0.00 /

+ (+0.00%)

, RDY

Dr. Reddy's

$40.22 /

+1.65 (+4.28%)

, AMRN

Amarin

$13.59 /

+0.34 (+2.57%)

Shares of Amarin (AMRN)…

Shares of Amarin (AMRN) after plummeting after the United States District Court for the District of Nevada ruled in favor of generic companies Dr. Reddy's (RDY) and Hikma Pharmaceuticals (HKMPF) in the patent litigation for its Vascepa capsule franchise. Six patents on the heart drug, which all expire in 2030, are invalid, ruled District Court Judge Miranda Du. In a statement tonight, Amarin said it "strongly disagrees with the ruling and will vigorously pursue all available remedies, including an appeal of the Court's decision and a preliminary injunction pending appeal to, if an ANDA is approved by FDA, prevent launch of generic versions of Vascepa in the United States." Based on Amarin's review of the FDA's website, an abbreviated new drug approval for Vascepa has not been approved, which would be required for launch of a generic product in U.S., the company added. As such, Amarin does not believe there is an impending generic launch by the litigants that would compete with Vascepa "at this time." Shares of Amarin are down 67%, or $9.04, to $4.54 in after-hours trading.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.